Zobrazeno 1 - 7
of 7
pro vyhledávání: '"M. K. Paris"'
Autor:
M. K. Paris, Alba A. Brandes
Publikováno v:
Critical Reviews in Oncology/Hematology. 50:121-128
Medulloblastoma (MB) is rare in adults, accounting for 1% of all primary tumours of the central nervous system (CNS). Based on the assumption that the disease pattern in adults is similar to that in children, adults with medulloblastoma are treated u
Autor:
Francesca Vastola, M. Ermani, Antonio Jirillo, S. Monfardini, Sara Lonardi, Alicia Tosoni, Haralabos Koussis, Alba A. Brandes, M. K. Paris, L. M. Pasetto, Umberto Basso
Publikováno v:
Annals of Oncology. 14:1727-1731
Background This study was a phase II study of third-line chemotherapy with carboplatin plus teniposide in patients with recurrent oligodendroglioma. Patients and methods Patients with oligodendroglioma progressive or recurrent after surgery, radiothe
Autor:
Alba A. Brandes, M. C. Marzola, Franco Bui, Franco Lumachi, M. K. Paris, Michele Povolato, Pietro Zucchetta, Guido Ferretti
Publikováno v:
Nuclear medicine communications. 23(11)
The purpose of this study was to analyse whether the use of Tc sestamibi scintimammography improves the positive predictive value of X-ray mammography. A series of 73 women (median age 51 years, range 35-79 years) with non-palpable, mammographically
Autor:
Chiara Messina, M. K. Paris, Giovanni Franco Zanon, Ornella Milanesi, Simone Cesaro, Roberta Corrò, Giorgio Svaluto, Luigi Zanesco, Piergiorgio Gamba
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 10(3)
Deep venous thrombosis is a possible complication of indwelling central venous catheters (CVC), with an incidence as high as 61%. We report a case of successful thrombolysis of a CVC-related right atrial thrombus in a pediatric cancer patient with re
Autor:
Alba A. Brandes, M. K. Paris, Paolo Iuzzolino, Franco Lumachi, S. Turazzi, Silvio Monfardini, Marina Paola Gardiman, Umberto Basso, F. Berti, P. Amista, Mario Ermani
Objectives: To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent gl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::842839fd3796bf34b77fd82a229fe655
http://hdl.handle.net/11577/2463894
http://hdl.handle.net/11577/2463894
Autor:
Mauro D'Amico, M. K. Paris, Micaela Stefani, Antonio Jirillo, Sara Lonardi, C. Caroti, Carlo Aschele, Luigi M. Gallo, Paolo Pronzato, S. Monfardini
Publikováno v:
ResearcherID
3577 Background: Sequential combinations of FU and IRI or OXA are currently used as 1st and 2nd line therapy for advanced CRC. Multiple trials are also investigating the concomitant use of the thre...
Autor:
Haralabos Koussis, A. Tosoni, Sara Lonardi, M. K. Paris, L. M. Pasetto, M. Ermani, Umberto Basso, Aa Brandes, A. Scola, Francesca Vastola
Publikováno v:
European Journal of Cancer Supplements. 1:S97